Table 1 Clinical characteristics of 94 breast cancer patients
| Â | All Patients | pCR | non-pCR | P-value |
|---|---|---|---|---|
(n = 94) | (n = 31) | (n = 63) | ||
Age years, median (IQR) | 47 (11) | 46 (11) | 48 (11) | 0.954 * |
Histological grade | Â | Â | Â | 0.405 * |
< 3 | 73 (77.66%) | 23 (74.19%) | 50 (79.37%) |  |
= 3 | 21 (22.34%) | 8 (25.81%) | 13 (13.83%) |  |
HER2 status | Â | Â | Â | 0.995 # |
Positive | 43 (45.74%) | 18 (58.06%) | 25 (39.68%) | Â |
Negative | 51 (54.26%) | 13 (41.94%) | 38 (60.32%) | Â |
ER status |  |  |  | < 0.001 * |
Positive | 64 (68.09%) | 15 (48.39%) | 49 (77.78%) | Â |
Negative | 30 (31.91%) | 16 (51.61%) | 14 (22.22%) | Â |
PR status | Â | Â | Â | 0.017 * |
Positive | 71 (75.53%) | 20 (64.52%) | 51 (80.95%) | Â |
Negative | 23 (24.47%) | 11 (35.48%) | 12 (19.05%) | Â |
Ki67 degree | Â | Â | Â | 0.014 * |
≤ 30% | 48 (51.06%) | 11 (35.48%) | 37 (58.73%) |  |
> 30% | 46 (48.94%) | 20 (64.52%) | 26 (41.27%) |  |
Adjuvant anthracyclines (E/D), cyclophosphamide (C), paclitaxel (T) regimens | Â | Â | Â | 0.365 # |
EC-T | 62 (65.96%) | 18 (58.06%) | 44 (69.84%) | Â |
DC-T | 15 (15.96%) | 6 (19.35%) | 9 (14.29%) | Â |
T-EC | 8 (8.51%) | 4 (12.90%) | 4 (6.35%) | Â |
EC | 3 (3.19%) | 0 (0%) | 3 (4.76%) | Â |
TC | 1 (1.06%) | 0 (0%) | 1 (1.59%) | Â |
T | 5 (5.32%) | 3 (9.68%) | 2 (3.17%) | Â |
Adjuvant mabs | Â | Â | Â | 0.002 # |
Trastuzumab | 35 (37.23%) | 16 (51.61%) | 19 (30.16%) | Â |
Trastuzumab + Patuzumab | 3 (3.19%) | 3 (9.68%) | 0 (0%) |  |
No | 56 (59.57%) | 12 (38.71%) | 44 (69.84%) | Â |
Adjuvant carboplatin | Â | Â | Â | 0.989 # |
Yes | 3 (3.19%) | 1 (3.23%) | 2 (3.17%) | Â |
No | 91 (96.81%) | 30 (96.77%) | 61 (96.83%) | Â |
Incomplete Prognostic information (< 3 years outcome) | 5 | 2 | 3 |  |
Relapse (≥ 3 years outcome) |  |  |  | 0.546 # |
No | 82 (92.13%) | 26 (89.66%) | 56 (93.33%) | Â |
Yes | 7 (7.87%) | 3 (10.34%) | 4 (6.67.%) | Â |
Relapse-free survival Months, median (IQR) | 55 (16) | 52 (16) | 56 (15) | 0.563 * |
Disease (≥ 3 years outcome) |  |  |  | 0.212 # |
No | 79 (88.76%) | 24 (82.76%) | 55 (91.67%) | Â |
Yes | 10 (11.24%) | 5 (17.24%) | 5 (8.33%) | Â |
Survival status (≥ 3 years outcome) |  |  |  | 0.484 # |
Alive | 88 (98.88%) | 29 (100%) | 59 (98.33%) | Â |
Dead | 1 (1.126%) | 0 (0%) | 1 (1.67%) | Â |